Mindray Medical: It is expected that the domestic business will achieve positive growth for the full year of 2026.

On March 28, Mindray Medical responded to investors on the interactive platform, stating that stock price fluctuations are influenced by various factors such as company performance, macroeconomics, industry policies, and market sentiment, and are not determined by a single factor. The company's production and operation are all normal. Due to the impact of multiple factors, the market capacity of various business lines in the domestic market has shrunk to varying degrees over the past two years. Although the company's market share is still steadily increasing, the domestic business has inevitably been negatively affected. It should be emphasized that the company believes this impact on Mindray is temporary. In the long run, in addition to the huge market share improvement space in IVD, Mindray's market share in minimally invasive surgery and interventional consumables is currently negligible, and the total market capacity of these two businesses is greater than IVD. In the future, with the gradual increase in minimally invasive surgery and interventional consumables, the long-term growth rate and resilience of the domestic business are expected to gradually improve. Therefore, it is expected that the domestic business will achieve positive growth for the full year in 2026. At the same time, with the high-end customer structure and product structure becoming more streamlined, the domestic business is expected to accelerate after 2027 and maintain a stable profit level. The above content does not constitute a performance commitment.